Oral administration of Limosilactobacillus reuteri VHProbi® M07 alleviates ovalbumin-induced allergic asthma in mice
PLOS ONE · 2025
DOI: 10.1371/journal.pone.0317587 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2025. Verfasst von Guoqing Meng und 5 weiteren Autor:innen. Beteiligte Einrichtung: College of Agriculture and Bioengineering, Heze University, Heze, China. Hauptthemen laut MEDLINE: Asthma, Limosilactobacillus reuteri, Ovalbumin, Probiotics. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Aims
Asthma is characterized by chronic airway inflammation, persistent cough, wheezing, and dyspnea. This study aimed to evaluate the efficacy of Limosilactobacillus reuteri VHProbi ® M07 (M07) administration in alleviate the asthma severity in a mice model. Methods and results In vitro studies confirmed that M07 can survive and proliferate within the gastrointestinal tract. BALB/c mice were administered M07 both before and after ovalbumin (OVA) challenge. Serum levels of OVA-specific immunoglobulin (Ig) E and IgG1, inflammatory cells and cytokines in bronchoalveolar lavage fluid were assessed, along with histopathological examination of lung tissue. Compared to the placebo (PLA) group, mice treated with M07 exhibited significantly lower levels of OVA-specific IgE and IgG1 ( P < 0.01). The counts of eosinophils and neutrophils were also significantly reduced in both the pretreated (PRE) group and post-treated (POS) group compared with the PLA group ( P < 0.01). Histological analysis of lung tissues verified the protective effects of M07 against inflammation, demonstrating reduced infiltration of inflammatory cells. Additionally, mice in the PRE and POS groups showed significantly increased levels of IL-10 ( P < 0.01), and significantly decreased levels of IL-5, IL-13, MCP-1, eotaxin, and tumor necrosis factor-α ( P < 0.01).
Conclusions
Oral administration of M07 mitigated key features of inflammatory responses in the OVA-induced mice asthma model. These findings suggest that M07 holds therapeutic potential for the treatment of allergic asthma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- College of Agriculture and Bioengineering, Heze University, Heze, China.
- College of Food Science and Engineering, Ocean University of China, Qingdao, China.
- Qingdao Vland Biotech Group Co., Ltd, Qingdao, China.
ORCID-Profile: Hongchang Cui, Zhi Duan
Zitieren
APA
Meng, G., Cui, H., Feng, C., Guo, C., Song, L., & Duan, Z. (2025). Oral administration of Limosilactobacillus reuteri VHProbi® M07 alleviates ovalbumin-induced allergic asthma in mice. PLOS ONE. https://doi.org/10.1371/journal.pone.0317587
Vancouver
Meng G, Cui H, Feng C, Guo C, Song L, Duan Z. Oral administration of Limosilactobacillus reuteri VHProbi® M07 alleviates ovalbumin-induced allergic asthma in mice. PLOS ONE. 2025. doi:10.1371/journal.pone.0317587
BibTeX
@article{Meng2025,
author = {Meng, Guoqing and Cui, Hongchang and Feng, Congrui and Guo, Chaoqun and Song, Lei and Duan, Zhi},
title = {Oral administration of Limosilactobacillus reuteri VHProbi® M07 alleviates ovalbumin-induced allergic asthma in mice},
journal = {PLOS ONE},
year = {2025},
doi = {10.1371/journal.pone.0317587}
}
EUVIMED